Phio 10-Q: Going-Concern Warning, $10.6M Cash, Nasdaq Bid-Price Deficiency
PHIO is trading near its 52-week low of $0.799 (0.1% above the low).
Summary
Phio's Q3 10-Q discloses substantial doubt about its ability to continue as a going concern with $10.6M of cash, plus a Nasdaq minimum bid-price deficiency after 21 straight closes below $1.00. Nine-month R&D rose 180% to $8.9M and the $6.36M ATM remains unused.
Key Events · Earnings and Guidance · PHIO
-
Going-Concern Warning Disclosed
Management states the company may not have sufficient cash to fund planned operations for at least the next 12 months from the release of these financial statements, and that continuation depends on raising equity, debt or a strategic transaction.
-
Cash Falls to $10.6M
Cash and equivalents were $10.6 million at September 30, 2026, down from $21.0 million at December 31, 2025, against a $12.3 million nine-month net loss and $10.3 million of operating cash burn.
-
Nasdaq Bid-Price Deficiency
The stock has closed below the $1.00 minimum bid for 21 consecutive business days as of the filing date; a 30-day deficiency triggers a Nasdaq notice, with 180 days to regain compliance. Stockholders' equity of $8.6 million remains above the $2.5 million listing requirement.
-
R&D Spending Up 180%
Nine-month research and development expense rose to $8.9 million from $3.1 million, driven by $4.5 million more in nonclinical toxicology, drug substance and clinical supply costs for PH-762; Q3 R&D alone was $3.1 million versus $1.2 million.
Analysis · PHIO · Life Sciences
Two disclosures in Phio's Q3 10-Q were absent from the same-day earnings 8-K: management now says existing cash may not fund operations for the next 12 months, and the stock has closed below $1.00 for 21 straight business days, putting a Nasdaq minimum-bid deficiency on the clock. Cash fell to $10.6M from $21.0M at year-end while nine-month R&D nearly tripled to $8.9M, so the burn is accelerating just as the company needs capital. The only near-term funding lever is a $6.36M ATM that has sold nothing, and 13.4M warrants at a $2.30 average strike are deeply out of the money against a $0.80 stock, so they will not be exercised for cash. The FDA response on the PH-762 Phase 2b plan, expected by end of November 2026, is the binary event that determines whether the company can raise on acceptable terms.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHIO was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.80 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.